Roth Capital Predicts Reduced Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Roth Capital reduced their Q1 2025 earnings per share (EPS) estimates for shares of Globus Medical in a note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings of $0.75 per share for the quarter, down from their previous estimate of $0.80. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.84 EPS, Q3 2025 earnings at $0.88 EPS, FY2025 earnings at $3.44 EPS, FY2026 earnings at $4.30 EPS and FY2027 earnings at $4.76 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. The company had revenue of $625.71 million for the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.57 EPS.

Other analysts have also recently issued reports about the company. Wells Fargo & Company upped their target price on Globus Medical from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Roth Mkm raised their target price on shares of Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler lifted their target price on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Bank of America increased their target price on shares of Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada boosted their price target on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.55.

Globus Medical Trading Up 2.1 %

Shares of NYSE:GMED opened at $83.42 on Wednesday. The firm has a 50 day simple moving average of $79.31 and a 200-day simple moving average of $73.10. Globus Medical has a twelve month low of $49.14 and a twelve month high of $87.22. The company has a market capitalization of $11.36 billion, a PE ratio of 124.51, a P/E/G ratio of 1.99 and a beta of 1.19.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. V Square Quantitative Management LLC acquired a new stake in Globus Medical during the third quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC acquired a new position in Globus Medical in the second quarter valued at approximately $33,000. Quarry LP grew its holdings in shares of Globus Medical by 698.4% during the third quarter. Quarry LP now owns 495 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Globus Medical by 230.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after purchasing an additional 385 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in Globus Medical in the second quarter valued at $52,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 30,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total value of $2,251,200.00. Following the sale, the director now directly owns 536,275 shares in the company, valued at $40,242,076. This represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Insiders sold 97,500 shares of company stock worth $7,674,950 over the last 90 days. Company insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.